

Contents in Print

Preface ix

QUALITY AND RELATED ISSUES

1. Quality Management Systems: Principles and Practice 1

Eva D. Quinley, MS, MT(ASCP)SBB, COA(ASQ), and Patricia C. Grace, RN, BSN

Background 1
Concepts in Quality 2
Quality Management Systems Approach 4
Evaluation of the Quality Management System 5
The Quality Management System in Practice 5
Key Points 23
References 24
Appendix 1-1. Glossary of Commonly Used Quality Terms 26
Appendix 1-2. Code of Federal Regulations Quality-Related References 28
Appendix 1-3. Suggested Quality Control Performance Intervals for Equipment
and Reagents 29

2. Facilities, Work Environment, and Safety 33

*J. Wade Atkins, MS, MT(ASCP)SBB, COA(ASQ), and
Colleen Bowman, MT(ASCP)SBB, COA(ASQ)*

Safety Program 35
Fire Prevention 39
Electrical Safety 40
Biosafety 41
Chemical Safety 48
Radiation Safety 53
Shipping Hazardous Materials 56
General Waste Management 56
Key Points 57
References 57
Appendix 2-1. Safety Regulations and Recommendations Applicable to
Health-Care Settings 61
Appendix 2-2. General Guidance for Safe Work Practices, Personal Protective
Equipment, and Engineering Controls 63

Appendix 2-3. Biosafety Level 2 Precautions	66
Appendix 2-4. Sample List of Hazardous Chemicals That May Be Encountered in a Blood Bank	67
Appendix 2-5. Chemical Categories and How to Work Safely with Them.	69
Appendix 2-6. Incidental Spill Response	71
Appendix 2-7. Managing Hazardous Chemical Spills	74

3. Regulatory Considerations in Transfusion Medicine and Cellular Therapies 77

*Joseph Schwartz, MD, MPH; Orijei Illoh, MD; and
Yvette C. Tanhehco, PhD, MD, MS*

FDA Oversight of Blood Establishments	78
Medical Laboratory Laws and Regulations	84
Local Laws, Hospital Regulations, and Accreditation	85
Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/PS)	86
Immune Effector Cells	89
Key Points	90
References	90

4. National Hemovigilance: The Current State 95

Kevin J. Land, MD; Barbee I. Whitaker, PhD; and Lynne Uhl, MD

International Hemovigilance	96
US Hemovigilance	97
Recipient Hemovigilance in the United States	100
Blood Donor Hemovigilance in the United States	103
Next Steps in US Hemovigilance	106
Key Points	112
References	113
Appendix 4-1. Protocol for Hospital Reporting Adverse Events to Blood Suppliers . .	116
Appendix 4-2. Severity Grading Tool for Blood Donor Adverse Events	124

B L O O D C O L L E C T I O N A N D T E S T I N G

5. Allogeneic and Autologous Blood Donor Selection 127

Debra A. Kessler, RN, MS, and Susan N. Rossmann, MD, PhD

Overview of Blood Donor Screening	127
Selection of Allogeneic Blood Donors	128
Abbreviated DHQ for Frequent Donors	132
Blood-Center-Defined Donor Eligibility Criteria	133
Recipient-Specific “Designated” or “Directed” Blood Donation	135
Key Points	137
References	137

6. Whole Blood and Apheresis Collection of Blood Components Intended for Transfusion. 141

Jason Acker, MBA, PhD, and Anna Razatos, PhD

Donor Preparation and Care	141
Blood Collection	145
Blood Component Storage	153
Postcollection Processing/Blood Component Modification	158
Quarantine of Blood Components	164
Labeling of Blood Components	164
Key Points	165
References	166

7. Infectious Disease Screening. 173

Lauren A. Crowder, MPH; Whitney R. Steele, PhD, MPH; and Susan L. Stramer, PhD

Historical Overview of Blood Donor Screening	173
Donor Screening Tests	177
Residual Infectious Risks of Transfusion	196
Screening for Specific Agents	199
Pathogen Inactivation Technology	215
Summary	217
Key Points	217
References	218

B L O O D G R O U P S

8. Molecular Biology and Immunology in Transfusion Medicine 229

Sean R. Stowell, MD, PhD, and James D. Gorham, MD, PhD

Analysis of DNA	229
Analysis of Protein	238
Basic Immunology	243
Key Points	251
References	251

9. Blood Group Genetics 255

Margaret A. Keller, PhD, and Sandy Wortman, MT(ASCP)^{CM}SBB

Genomic Organization and Gene Regulation.	256
Genetic Variation	262
Inheritance of Genetic Traits	266
Structural Variation	270
Chimerism	273
Gene Position Effects	274

Genetic Modifiers of Blood Group Antigen Expression	274
Population Genetics	275
Relationship Testing	278
Blood Group Gene Mapping	279
Gene, Protein, and Blood Group Terminology	280
Blood Group Genomics	281
Summary	291
Key Points	292
References	293

10. ABO and Other Carbohydrate Blood Group Systems 297

Martin L. Olsson, MD, PhD, and Julia S. Westman, PhD

The ABO system (001)	297
The H System (018)	310
The LE System (007)	313
I and i Antigens of the I Blood Group System (027) and I Blood Group Collection . .	315
P1PK (003) and GLOB (028) Blood Group Systems	318
The FORS Blood Group System (031)	323
The SID Blood Group System (038)	323
Key Points	323
References	324

11. The Rh System 329

Thierry Peyrard, PharmD, PhD, EurSpLM, and Franz F. Wagner, MD

Historical Perspective	329
Terminology	332
Rh Locus	333
RHD Genotype	334
Antigens	337
Rh Genotyping	346
Rh _{null} Syndrome and the RhAG (030) Blood Group System	347
Antibodies to Rh Blood Group System Antigens	347
Technical Considerations for Rh Typing	348
Key Points	349
References	350

12. Other Blood Group Systems and Antigens 355

Cami Melland, MLS(ASCP)^{CM}SBB, and Sandra Nance, MS, MT(ASCP)SBB

The MNS System (002)	359
The LU System (005)	363
The KEL (006) and Xk (019) Systems	364
The FY System (008)	368
The JK System (009)	370
The DI System (010)	372
The YT System (011)	373
The XG System (012)	374

The SC System (013)	374
The DO System (014)	374
The CO System (015)	375
The LW System (016)	375
The CH/RG System (017)	377
The GE System (020)	377
The CROM System (021)	378
The KN System (022)	378
The IN System (023)	379
The OK System (024)	379
The RAPH System (025)	379
The JMH System (026)	379
The GIL System (029)	380
The RHAG System (030)	380
The JR System (032)	380
The LAN System (033)	380
The VEL System (034)	381
The CD59 System (035)	381
The AUG System (036)	381
The KANNO System (037)	382
The SID System (038)	382
The CTL2 System (039)	382
Antigens that Do Not Yet Belong to a Blood Group System	382
Erythroid Phenotypes Caused by Mutations in Transcription Factor Genes	384
Key Points	384
References	385

13. Identification of Antibodies to Red Cell Antigens 389

*Lay See Er, MSTM, SBB(ASCP)^{CM}, COA(ASQ), and
Debra J. Bailey, MT(ASCP)SBB*

Basic Concepts in Red Cell Antigen Expression	390
Initial Antibody Identification Considerations	391
Basic Antibody Identification	394
Complex Antibody Identification	402
Selected Procedures	414
Considerations Following Antibody Identification	421
Immunohematology Reference Laboratories	424
Key Points	424
References	425
Suggested Readings	428

14. The Positive Direct Antiglobulin Test and Immune-Mediated Hemolysis 429

P. Dayand Borge Jr, MD, PhD, and Paul M. Mansfield, MT(ASCP)^{CM}SBB

The DAT	430
Autoimmune Hemolytic Anemia	434
Drug-Induced Immune Hemolytic Anemia	445

Key Points	449
References	449
Appendix 14-1. Drugs Associated with Immune Hemolytic Anemia	452

15. Platelet and Granulocyte Antigens and Antibodies 457

David F. Stroncek, MD, and Ralph R. Vassallo, MD, FACP

Platelet Antigens and Antibodies	457
Granulocyte Antigens and Antibodies	469
Key Points	473
References	473

16. The HLA System 479

*Jeremy Ryan Peña, MD, PhD; Arthur B. Eisenbrey III, MD, PhD; and
Patricia M. Kopko, MD*

Biochemistry, Tissue Distribution, and Structure	479
Genetics of the MHC	484
HLA Typing	488
Other Non-HLA Histocompatibility Determinants	489
Crossmatching and Detection of HLA Antibodies	490
The HLA System and Transfusion	491
HLA Testing and Transplantation	493
Other Clinically Significant Aspects of HLA	495
Clinical Consultation in HLA	497
Regulatory Aspects of Clinical Histocompatibility	498
Future Directions	498
Summary	499
Key Points	499
References	499

ESSENTIALS OF TRANSFUSION PRACTICE

17. Transfusion-Service-Related Activities: Pretransfusion Testing and Storage, Monitoring, Processing, Distribution, and Inventory Management of Blood Components 503

Caroline R. Alquist, MD, PhD, and Sarah K. Harm, MD

Samples and Requests	503
Pretransfusion Testing of Recipient Blood	504
Blood and Blood Component Storage and Monitoring	509
Pretransfusion Processing	518
Distribution	522
Issuing of Components	523
Inventory Management	527
Key Points	529

References	530
Appendix 17-1. Sources of False-Positive Results in Antiglobulin Testing	533
Appendix 17-2. Sources of False-Negative Results in Antiglobulin Testing	534
Appendix 17-3. Causes of Positive Pretransfusion Test Results.	535
18. Administration of Blood Components	537
<i>Melanie Jorgenson, RN, BSN, LSSGB</i>	
Events and Considerations Before Dispensing Components	537
Blood Component Transportation and Dispensing	542
Blood Administration	543
Documentation of the Transfusion	547
Unique Transfusion Settings	548
Conclusion	549
Key Points	549
References	550
19. Hemotherapy Decisions and Their Outcomes	553
<i>Nadine Shehata, MD, FRCP, and Yunchuan Delores Mo, MD</i>	
Red Blood Cell Transfusion.	553
Platelet Transfusion	561
Plasma Transfusion	567
Cryoprecipitate Transfusion	569
Granulocyte Transfusion.	570
Massive Transfusion Protocols	571
Key Points	573
References	573
20. Patient Blood Management	583
<i>Steven M. Frank, MD, and Nicole R. Guinn, MD</i>	
Definition and Scope of Patient Blood Management	583
Resources to Support a PBM Program	584
Patient Blood Management Standards and Certification	585
Methods of Patient Blood Management	585
Data Collection	600
Extremes of Transfusion	605
Summary	606
Key Points	607
References	607
21. Approaches to Blood Utilization Auditing	613
<i>Ira A. Shulman, MD; Jay Hudgins, DO; and Irina Maramica, MD, PhD, MBA</i>	
The Auditing Process	614
Defining Audit Criteria	615
Types of Blood Utilization Review	617
Blood Utilization Review of Transfusions to High-Risk Patients	620

The Role of a Computerized Provider Order Entry System in Blood Utilization	
Review	620
Use of “Big Data” to Assess Performance and Progress Measures in	
Transfusion Medicine	621
Key Points	623
References	624

22. Noninfectious Complications of Blood Transfusion 627

Eldad A. Hod, MD, and Richard O. Francis, MD, PhD

Hemovigilance	627
Recognition and Evaluation of a Suspected Transfusion Reaction	627
Acute or Immediate Transfusion Reactions	634
Delayed Transfusion Reactions	648
Fatality Reporting Requirements	652
Key Points	653
References	653

SPECIAL PATIENTS AND SITUATIONS

23. Perinatal Issues in Transfusion Practice 659

Lani Lieberman, MD; Gwen Clarke, MD; and Annika M. Svensson, MD, PhD

Hemolytic Disease of the Fetus and Newborn	659
Pregnancy-Related Thrombocytopenia	665
Key Points	668
References	668

24. Neonatal and Pediatric Transfusion Practice 673

Edward C.C. Wong, MD, and Rowena C. Punzalan, MD

Hematopoiesis, Coagulation, and Physiology	673
RBC Transfusion in Neonates	675
RBC Transfusion in Infants Older than 4 Months and Children	682
Platelet Transfusion in Neonates and Children	685
Plasma and Cryoprecipitate Transfusion in Neonates and Children	687
Granulocyte Transfusion in Neonates and Children	688
Other Considerations Common to Transfusion of Neonates and Children	689
Adverse Effects and Prevention	694
Key Points	695
References	696

25. Therapeutic Apheresis. 705

Jennifer Webb, MD, MSCE, and Chester Andrzejewski Jr, PhD, MD

General Principles	705
Device Modalities	706
Patient Evaluation and Management	707

Vascular Access	709
Anticoagulation	711
Adverse Effects	711
Pediatric Apheresis	713
Therapeutic Apheresis Indications	713
Therapeutic Apheresis Procedure Documentation, Payment, and Provider Credentialing	727
Key Points	729
References	730
26. The Collection and Processing of Hematopoietic Progenitor Cells	737
<i>Laura S. Connelly-Smith, MBBCh, DM, and Michael L. Linenberger, MD, FACP</i>	
Clinical Utility	737
Histocompatibility, Donor Type, and Graft Source	741
HPC Collection	743
Processing Human Progenitor Cells	748
Specialized Cell-Processing Methods	750
Cryopreservation	751
Quality Control	752
Shipping and Transporting HPC Cellular Products	754
Patient Care	754
Regulatory and Accreditation Considerations	756
Conclusion	757
Key Points	757
References	758
27. Transfusion Support for Hematopoietic Stem Cell Transplant Recipients	767
<i>James M. Kelley, MD, PhD, and Melissa M. Cushing, MD</i>	
ABO Compatibility for Blood Component Selection Following HSCT	768
Blood Component Support for HSCT Patients	772
Pediatric Considerations	773
Key Points	774
References	774
28. Human Tissue Allografts and the Hospital Transfusion Service	777
<i>Annette J. Schlueter, MD, PhD; Fran Rabe, MS; and Cassandra D. Josephson, MD</i>	
Tissue Donation and Transplantation	777
Federal Regulations, State Laws, and Professional Standards	782
Hospital Tissue Services	784
Key Points	789
References	790
Index	793

Contents Online

METHODS

1. General Laboratory Methods

- Method 1-1. Shipping Hazardous Materials
- Method 1-2. Monitoring Temperature During Shipment of Blood
- Method 1-3. Treating Incompletely Clotted Specimens
- Method 1-4. Solution Preparation Procedure
- Method 1-5. Serum Dilution Procedure
- Method 1-6. Dilution of Percentage Solutions Procedure
- Method 1-7. Preparing a 3% Red Cell Suspension
- Method 1-8. Preparing and Using Phosphate Buffer
- Method 1-9. Reading and Grading Tube Agglutination

2. Red Cell Typing Methods

- Method 2-1. Determining ABO Group of Red Cells—Slide Test
- Method 2-2. Determining ABO Group of Red Cells and Serum—Tube Test
- Method 2-3. Determining ABO Group of Red Cells and Serum—Microplate Test
- Method 2-4. Initial Investigation of ABO Grouping Discrepancies Procedure
- Method 2-5. Detecting Weak A and B Antigens and Antibodies by Cold Temperature Enhancement
- Method 2-6. Confirming Weak A and B Antigens Using Enzyme-Treated Red Cells
- Method 2-7. Confirming Weak A or B Subgroup by Adsorption and Elution
- Method 2-8. Testing Saliva for A, B, H, Le^a, and Le^b Antigens
- Method 2-9. Confirming Anti-A₁ in an A₂ or Weak A Subgroup
- Method 2-10. Resolving ABO Discrepancies Caused by Unexpected Alloantibodies
- Method 2-11. Determining Serum Group Without Centrifugation
- Method 2-12. Determining Rh(D) Type—Slide Test
- Method 2-13. Determining Rh(D) Type—Tube Test
- Method 2-14. Determining Rh(D) Type—Microplate Test
- Method 2-15. Testing for Weak D
- Method 2-16. Preparing and Using Lectins
- Method 2-17. Removing Autoantibody by Warm Saline Washes
- Method 2-18. Using Sulfhydryl Reagents to Disperse Autoagglutination
- Method 2-19. Using Gentle Heat Elution to Test Red Cells with a Positive DAT Result
- Method 2-20. Dissociating IgG by Chloroquine for Antigen Testing of Red Cells with a Positive DAT Result
- Method 2-21. Using Acid Glycine/EDTA to Remove Antibodies from Red Cells
- Method 2-22. Separating Transfused from Autologous Red Cells by Simple Centrifugation
- Method 2-23. Separating Transfused from Autologous Red Cells in Patients with Hemoglobin S Disease

3. Antibody Detection, Identification, and Compatibility Testing

- Method 3-1. Using Immediate-Spin Compatibility Testing to Demonstrate ABO Incompatibility
- Method 3-2. Saline Indirect Antiglobulin Test Procedure
- Method 3-3. Albumin or LISS-Additive Indirect Antiglobulin Test Procedure
- Method 3-4. LISS-Suspension Indirect Antiglobulin Test Procedure
- Method 3-5. PEG Indirect Antiglobulin Test Procedure
- Method 3-6. Prewarming Procedure
- Method 3-7. Detecting Antibodies in the Presence of Rouleaux—Saline Replacement
- Method 3-8. Preparing Ficin Enzyme Stock, 1% w/v
- Method 3-9. Preparing Papain Enzyme Stock, 1% w/v
- Method 3-10. Standardizing Enzyme Procedures
- Method 3-11. Evaluating Enzyme-Treated Red Cells
- Method 3-12. One-Stage Enzyme Procedure
- Method 3-13. Two-Stage Enzyme Procedure
- Method 3-14. Performing a Direct Antiglobulin Test
- Method 3-15. Antibody Titration Procedure
- Method 3-16. Using Sulfhydryl Reagents to Distinguish IgM from IgG Antibodies
- Method 3-17. Using Plasma Inhibition to Distinguish Anti-Ch and -Rg from Other Antibodies with Similar Characteristics
- Method 3-18. Treating Red Cells Using DTT or AET
- Method 3-19. Neutralizing Anti-Sd^a with Urine
- Method 3-20. Adsorption Procedure
- Method 3-21. Using the American Rare Donor Program

4. Investigation of a Positive DAT Result

- Method 4-1. Cold-Acid Elution Procedure
- Method 4-2. Glycine-HCl/EDTA Elution Procedure
- Method 4-3. Heat Elution Procedure
- Method 4-4. Lui Freeze-Thaw Elution Procedure
- Method 4-5. Cold Autoadsorption Procedure
- Method 4-6. Determining the Specificity of Cold-Reactive Autoagglutinins
- Method 4-7. Cold Agglutinin Titer Procedure
- Method 4-8. Adsorbing Warm-Reactive Autoantibodies Using Autologous Red Cells
- Method 4-9. Adsorbing Warm-Reactive Autoantibodies Using Allogeneic Red Cells
- Method 4-10. Polyethylene Glycol Adsorption Procedure
- Method 4-11. Performing the Donath-Landsteiner Test
- Method 4-12. Detecting Drug Antibodies by Testing Drug-Treated Red Cells
- Method 4-13. Detecting Drug Antibodies by Testing in the Presence of Drug

5. Hemolytic Disease of the Fetus and Newborn

- Method 5-1. Testing for Fetomaternal Hemorrhage—The Rosette Test
- Method 5-2. Testing for Fetomaternal Hemorrhage—Modified Kleihauer-Betke Test
- Method 5-3. Using Antibody Titration Studies to Assist in Early Detection of Hemolytic Disease of the Fetus and Newborn

6. Blood Collection, Component Preparation, and Storage

Method 6-1. Screening Female Donors for Acceptable Hemoglobin Level—Copper Sulfate Method

Method 6-2. Preparing the Donor's Arm for Blood Collection

Method 6-3. Collecting Blood and Samples for Processing and Testing

Method 6-4. Preparing Red Blood Cells from Whole Blood

Method 6-5. Preparing Prestorage Red Blood Cells Leukocytes Reduced from Whole Blood

Method 6-6. Using High-Concentration Glycerol to Cryopreserve Red Cells—Meryman Method

Method 6-7. Using High-Concentration Glycerol to Cryopreserve Red Cells—Valeri Method

Method 6-8. Checking the Adequacy of Deglycerolization of Red Blood Cells

Method 6-9. Preparing Fresh Frozen Plasma from Whole Blood

Method 6-10. Preparing Cryoprecipitated AHF from Whole Blood

Method 6-11. Thawing and Pooling Cryoprecipitated AHF

Method 6-12. Preparing Platelets from Whole Blood

Method 6-13. Removing Plasma from Platelets (Volume Reduction)

7. Transplantation of Cells and Tissue

Method 7-1. Infusing Cryopreserved Hematopoietic Cells

Method 7-2. Processing Umbilical Cord Blood

Method 7-3. Investigating Adverse Events and Infections Following Tissue Allograft Use

8. Quality Control Methods

Method 8-1. Validating Copper Sulfate Solution

Method 8-2. Calibrating Liquid-in-Glass Laboratory Thermometers

Method 8-3. Calibrating Electronic Oral Thermometers

Method 8-4. Testing Refrigerator Alarms

Method 8-5. Testing Freezer Alarms

Method 8-6. Calibrating Centrifuges for Platelet Separation

Method 8-7. Calibrating a Serologic Centrifuge for Immediate Agglutination

Method 8-8. Calibrating a Serologic Centrifuge for Washing and Antiglobulin Testing

Method 8-9. Testing Automatic Cell Washers

Method 8-10. Monitoring Cell Counts of Apheresis Components

Method 8-11. Counting Residual White Cells in Leukocyte-Reduced Blood and Components—Manual Method

A P P E N D I C E S

Appendix 1. Normal Values in Adults

Appendix 2. Selected Normal Values in Children

Appendix 3. Typical Normal Values in Tests of Hemostasis and Coagulation (Adults)

Appendix 4. Coagulation Factor Values in Platelet Concentrates

Appendix 5. Approximate Normal Values for Red Cell, Plasma, and Blood Volumes

Appendix 6. Blood Group Antigens Assigned to Systems

- Appendix 7. Examples of Gene, Antigen, and Phenotype Symbols in Conventional and International Society of Blood Transfusion Terminology
Appendix 8. Examples of Correct and Incorrect Terminology
Appendix 9. Distribution of ABO/Rh Phenotypes by Race or Ethnicity
Appendix 10. Abbreviations Used in the *Technical Manual*, 20th Edition

A C K N O W L E D G M E N T

Special thanks to Maureen Beaton, MT(ASCP)BB, COA(ASQ),
for review of the methods and appendices.

